Abstract

The osteoblast differentiation capacity of skeletal stem cells (SSCs) must be tightly regulated, as inadequate bone formation results in low bone mass and skeletal fragility, and over-exuberant osteogenesis results in heterotopic ossification (HO) of soft tissues. RUNX2 is essential for tuning this balance, but the mechanisms of posttranslational control of RUNX2 remain to be fully elucidated. Here, we identify that a CK2/HAUSP pathway is a key regulator of RUNX2 stability, as Casein kinase 2 (CK2) phosphorylates RUNX2, recruiting the deubiquitinase herpesvirus-associated ubiquitin-specific protease (HAUSP), which stabilizes RUNX2 by diverting it away from ubiquitin-dependent proteasomal degradation. This pathway is important for both the commitment of SSCs to osteoprogenitors and their subsequent maturation. This CK2/HAUSP/RUNX2 pathway is also necessary for HO, as its inhibition blocked HO in multiple models. Collectively, active deubiquitination of RUNX2 is required for bone formation and this CK2/HAUSP deubiquitination pathway offers therapeutic opportunities for disorders of inappropriate mineralization.

Runx2 is essential for tuning the generation of bone from skeletal stem cells (SSCs). Here, the authors demonstrate that the CK2/HAUSP pathway stabilizes RUNX2 protein thereby regulating the commitment of SSCs to osteoprogenitors as well as their subsequent maturation, and that inhibition of this pathway can block heterotopic ossification.

Details

Title
A RUNX2 stabilization pathway mediates physiologic and pathologic bone formation
Author
Jung-Min, Kim 1 ; Yeon-Suk, Yang 1 ; Park, Kwang Hwan 2 ; Ge Xianpeng 1 ; Xu, Ren 3   VIAFID ORCID Logo  ; Li, Na 3 ; Song Minkyung 4 ; Chun Hyunho 5 ; Bok Seoyeon 6 ; Charles, Julia F 7   VIAFID ORCID Logo  ; Filhol-Cochet Odile 8   VIAFID ORCID Logo  ; Boldyreff Brigitte 9 ; Dinter, Teresa 10 ; Yu, Paul B 10   VIAFID ORCID Logo  ; Kon Ning 11 ; Gu, Wei 12   VIAFID ORCID Logo  ; Takarada Takeshi 13   VIAFID ORCID Logo  ; Greenblatt, Matthew B 6 ; Jae-Hyuck, Shim 14   VIAFID ORCID Logo 

 University of Massachusetts Medical School, Department of Medicine, Worcester, USA (GRID:grid.168645.8) (ISNI:0000 0001 0742 0364) 
 Yonsei University College of Medicine, Department of Orthopaedic Surgery, Seoul, South Korea (GRID:grid.15444.30) (ISNI:0000 0004 0470 5454) 
 Xiamen University, State Key Laboratory of Cellular Stress Biology, Fujian, China (GRID:grid.12955.3a) (ISNI:0000 0001 2264 7233) 
 Sungkyunkwan University, Department of integrative biotechnology, Suwon, South Korea (GRID:grid.264381.a) (ISNI:0000 0001 2181 989X) 
 Korea Advanced Institute of Science and Technology, Department of Mathematical Sciences, Daejeon, South Korea (GRID:grid.37172.30) (ISNI:0000 0001 2292 0500) 
 Weill Cornell Medical College, Department of Pathology and Laboratory Medicine, New York, USA (GRID:grid.5386.8) (ISNI:000000041936877X) 
 Brigham and Women’s Hospital, Harvard Medical School, Department of Orthopedics and Medicine, Boston, USA (GRID:grid.5386.8) 
 Commissariat à l’Énergie Atomique et aux Énerigies Alternatives Grenoble, INSERM U1036, pour le Vivant/Biologie du Cancer et de l’Infection, Grenoble, France (GRID:grid.457348.9) 
 KinaseDetect ApS, Krusaa, Denmark (GRID:grid.457348.9) 
10  Brigham and Women’s Hospital, Harvard Medical School, Division of Cardiovascular Medicine, Department of Medicine, Boston, USA (GRID:grid.457348.9) 
11  Institute of Cancer Genetics, College of Physicians and Surgeons of Columbia University, New York, USA (GRID:grid.21729.3f) (ISNI:0000000419368729) 
12  Institute of Cancer Genetics, College of Physicians and Surgeons of Columbia University, New York, USA (GRID:grid.21729.3f) (ISNI:0000000419368729); College of Physicians and Surgeons of Columbia University, Department of Pathology and Cell Biology, New York, USA (GRID:grid.21729.3f) (ISNI:0000000419368729) 
13  Okayama University Graduate School of Medicine, Department of Regenerative Science, Okayama, Japan (GRID:grid.261356.5) (ISNI:0000 0001 1302 4472) 
14  University of Massachusetts Medical School, Department of Medicine, Worcester, USA (GRID:grid.168645.8) (ISNI:0000 0001 0742 0364); University of Massachusetts Medical School, Li Weibo Institute for Rare Diseases Research, Worcester, USA (GRID:grid.168645.8) (ISNI:0000 0001 0742 0364) 
Publication year
2020
Publication date
2020
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2400097260
Copyright
© The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.